117 completed, 50 unknown, 23 recruiting, 14 not yet recruiting. 93 Phase 1, 51 Not applicable, 38 Phase 2, 16 Phase 3, 15 Phase 4.
Follow Safety: new trials by email Literature Review of Safety trials Research Report on Safety
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells, Placebo - Spinal Cord Injury, Safety | Phase 2 | Not yet recruiting | XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | 60 | 2028-05-25 | 2025-11-25 |
| A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug), Placebo - Safety, Tolerability | Phase 1 | Not yet recruiting | Hangzhou Yirui Pharmaceutical Technology Co., Ltd | 64 | 2027-04-01 | 2026-07-30 |
| A First-in-Human SAD and MAD Study in HV to Evaluate Oral YR011 Tablet Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug), Placebo - Safety, Tolerability | Phase 1 | Not yet recruiting | Hangzhou Yirui Pharmaceutical Technology Co., Ltd | 64 | 2027-01-01 | 2026-10-16 |
| To Evaluate the Safety and Efficacy of Hemay5394 in Patients With Mild to Moderate Atopic Dermatitis Hemay5394 group, Control group - Safety, Efficiency | Phase 2 | Not yet recruiting | Hemay Pharmaceutical PTY. LTD. | 90 | 2026-11-01 | 2026-10-16 |
| Evaluating a Shared Decision-making Intervention for Families About Firearm Storage Family Safety Check-In, AAP Resource - Safety | Not applicable | Not yet recruiting | Seattle Children's Hospital | 548 | 2026-10-01 | 2026-04-16 |
| Phase 1/2 Clinical Study of HY07121 for Injection (Subcutaneous) in Patients With Advanced Solid Tumors Test Product HY07121 for Injection (Subcutaneous) - Safety, Tolerability | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 254 | 2026-09-08 | 2026-08-27 |
| A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV) GenSci142 capsule, clindamycin phosphate vaginal cream - Randomized, Open-label | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 42 | 2026-08-15 | 2026-10-15 |
| Evaluation of Allergenicity by HRIPT and Phototest Blancy Pro - Safety | Not applicable | Completed | Brainfarma Industria Química e Farmacêutica S/A | 55 | 2026-07-13 | 2026-09-16 |
| Tamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH Tamsulosin 0.4 mg + Tadalafil 2.5 mg, Tamsulosin 0.4 mg + Tadalafil 5 mg, Tamsulosin 0.4 mg - Safety, Efficacy | Not applicable | Recruiting | Ain Shams University | 90 | 2026-07-01 | 2026-07-23 |
| Short-Term Safety and Performance of Two Wound Dressings Evaluation Politix Fiber arm - Chronic Wound Care, Local Infection | Not applicable | Not yet recruiting | Sebastian Probst | 60 | 2026-06-15 | 2026-05-08 |
| Evaluation of a Sexual Violence and Intimate Partner Violence Primary Prevention Program Implemented in Drinking Establishments Safe Night Out Program, No Safe Night Out - Intimate Partner Violence (IPV), Sexual Violence | Not yet recruiting | University of California, San Diego | 650 | 2026-06-01 | 2026-02-27 | |
| The Relationship Between Nurses' Perception Of Safety Culture And Patients' Sense Of Safety Nursing Personnel, Safety | Not yet recruiting | Uludag University | 206 | 2026-05-01 | 2026-05-07 | |
| Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer Psilocybin-assisted Psychotherapy - Demoralization, Safety | Phase 1 | Recruiting | Gustavo Vazquez | 15 | 2026-04-01 | 2026-03-18 |
| Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy IRL757, Placebo - PARKINSON DISEASE (Disorder), Apathy | Phase 1 / Phase 2 | Recruiting | Integrative Research Laboratories AB | 75 | 2026-02-18 | 2026-09-03 |
| Safety Exploration and Evaluation of Dexmedetomidine Hydrochloride Nasal Spray for Pre-anesthesia Sedation in Low-Monitoring Settings Dexmedetomidine hydrochloride nasal spray, Placebo - Dexmedetomidine, Sedation | Phase 4 | Not yet recruiting | Sichuan Provincial People's Hospital | 564 | 2026-01-10 | 2025-12-23 |
| Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an Ampule Pasireotide cartridge with reusable ServoPen, Pasireotide ampule with syringe - Pharmacokinetics, Safety | Phase 1 | Completed | RECORDATI GROUP | 40 | 2025-12-01 | 2026-02-04 |
| A Study of GensSci098 in Subjects With Graves' Disease GenSci098 - Safety, Tolerability | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 24 | 2025-11-21 | 2026-02-17 |
| A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market Pneumococcal 20-valent conjugate vaccine - Pneumococcal Immunization, Safety | Recruiting | Pfizer | 660 | 2025-11-13 | 2026-03-12 | |
| Safety and Efficacy of Papillary Versus NonPapillary Access During Percutaneous Nephrolithotomy Papillary access puncture, Non-papillary access puncture - Safety, Efficacy | Not applicable | Recruiting | Ain Shams University | 70 | 2025-11-01 | 2026-10-02 |
| Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy Low dose of Megestrol Acetate Oral Suspension combined with standard therapy, Medium dose of Megestrol Acetate Oral Suspension combined with standard therapy, High dose of Megestrol Acetate Oral Suspension combined with standard therapy - Efficacy, Safety | Phase 1 | Not yet recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 132 | 2025-09-29 | 2025-08-19 |
Showing 20 of 224. Sign in to see all of them.
COVID-19 (5) · Alzheimer Disease (3) · Heart Failure (3) · Respiratory Aspiration (3) · Spinal Cord Injuries (3) · Stroke (3) · Arthritis, Rheumatoid (2) · Breast Neoplasms (2) · Colorectal Neoplasms (2) · Drug-Related Side Effects and Adverse Reactions (2) · Influenza, Human (2) · Lung Diseases, Interstitial (2) · Marijuana Abuse (2) · Mpox, Monkeypox (2) · Psychological Well-Being (2)
Pathological Conditions, Signs and Symptoms (17) · Respiratory Tract Diseases (15) · Neoplasms (14) · Pathologic Processes (14) · Nervous System Diseases (13) · Infections (12) · Central Nervous System Diseases (11) · Neoplasms by Site (11) · Cardiovascular Diseases (10) · Urogenital Diseases (10) · Virus Diseases (10) · Brain Diseases (9) · Immune System Diseases (9) · Lung Diseases (9) · Endocrine System Diseases (8)
Control Groups (3) · Influenza Vaccines (3) · AZD9977 (2) · Bevacizumab (2) · Deoxycholic Acid (2) · GV-971 (2) · Injections (2) · Midazolam (2) · Morphine (2) · Radiosurgery (2) · Safety (2) · Suspensions (2) · microcrystalline cellulose (2) · velsecorat (2) · ((3-methoxythiophen-2-yl)methyl)((2-(9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethyl))amine (1)
AstraZeneca (12) · Pfizer (8) · Changchun GeneScience Pharmaceutical Co., Ltd. (5) · Ain Shams University (3) · MicuRx (3) · Sichuan Huiyu Pharmaceutical Co., Ltd (3) · Stemirna Therapeutics (3) · Tanta University (3) · The Affiliated Hospital of Qingdao University (3) · Anhui Provincial Hospital (2) · Astellas Pharma Europe B.V. (2) · CannaXan GmbH (2) · Duke University (2) · First Affiliated Hospital Xi'an Jiaotong University (2) · Galderma R&D (2)
China (51) · United States (43) · United Kingdom (15) · Germany (13) · Canada (9) · Egypt (8) · Spain (8) · South Korea (7) · France (6) · Sweden (6) · Denmark (5) · Poland (5) · Australia (4) · Belgium (4) · Bulgaria (4)
Katherine Bunge, MD (3) · Mayfong Mayxay, doctor (3) · Sharon L Hillier, PhD (3) · Abdelrahman G Salman, MD (2) · Frederick Beddingfield, III, MD, PhD (2) · Julia Solnier, PhD (2) · Limin Rong, prof and M.D (2) · Yi Han, doctorate (2) · Aaron Samuels, MD (1) · Adrianne C. Feldstein, MD, MS (1) · Alberto Torres Zamudio, MD (1) · Ali R Djalilian, MD (1) · Alice Mannocci (1) · Andrea Ludwig-Sengpiel, Dr. (1)
PMID 12750546, PMID 16019852, PMID 17000941, PMID 17110769, PMID 18470620, PMID 19219697, PMID 20921468, PMID 21791539, PMID 22397650, PMID 22966018, PMID 23352749, PMID 24071851, PMID 24732979, PMID 25109877, PMID 25176015, PMID 25243564, PMID 25326492, PMID 25780077, PMID 26342236, PMID 26873727, PMID 27162549, PMID 27477896, PMID 27853199, PMID 27902652, PMID 28390780, PMID 29504252, PMID 29557719, PMID 30121146, PMID 30244209, PMID 30741494, PMID 30777086, PMID 30855740, PMID 30855741, PMID 30985861, PMID 31424503, PMID 31601801, PMID 32033600, PMID 32087818, PMID 32171764, PMID 32673497, PMID 32715381, PMID 32853681, PMID 33148815, PMID 33538338, PMID 33736819, PMID 34428445, PMID 34447992, PMID 34487721, PMID 34890373, PMID 35142858
2015 (4), 2009 (2), 2017 (2), 2018 (2), U19AI120249 (2), 2014 (1), 2019 (1), P30CA047904 (1), R01HD102402 (1), R44AG067907 (1), U01CE003735 (1), U01HL125388 (1), U01HL126088 (1)